Study Links Tumor Methylation to Endometrial Cancer Recurrence

Researchers at the University of California, San Francisco profiled DNA methylation in 219 endometrial tumors to identify recurrence-risk patterns.

Updated on Nov. 13, 2026 in Cancer

Isometric editorial illustration of a row of unlabeled slides in a tray beside an amber vial, on a flat teal and cream field. — University of California, San Francisco researchers linked DNA methylation patterns in 219 endometrial tumors to recurrence risk in early-stage disease, presented at AMP 2026 in Seattle. AI Illustration. Upload story photo >

University of California, San Francisco researchers profiled DNA methylation in 219 tumors and identified patterns associated with recurrence of low-grade, limited-stage, copy number-low endometrioid adenocarcinoma. The findings were presented as a poster at the AMP 2026 Annual Meeting in Seattle.

Why it matters

Methylation changes correlated with recurrence risk, suggesting epigenetic profiling may help distinguish patients who share similar clinical and pathologic characteristics. Such tools could inform decisions about follow-up care for patients with early-stage disease.

The poster reports 219 profiled tumors, with methylation-defined clusters showing enrichment in CTNNB1 and DICER1 mutations and chromosome 1q copy number gains. The stub does not report a recurrence-rate comparator or an independent validation cohort, so the strength of the association remains unclear.

The players

University of California, San Francisco

A public research university in San Francisco that is one of the leading academic medical centers in the United States.

The details

Researchers profiled DNA methylation across endometrial tumors and grouped them into clusters, then linked methylation changes to recurrence risk in low-grade, limited-stage, copy number-low endometrioid adenocarcinoma. The study was presented as a poster session at the AMP 2026 Annual Meeting.

Nov. 13, 2026: Poster session presenting the UCSF methylation recurrence study at the AMP 2026 Annual Meeting in Seattle.

Health Landscape

The findings build on molecular classification of endometrial cancer established by The Cancer Genome Atlas, which divided tumors into genomic subgroups. Using methylation patterns to refine risk within the copy number-low group extends that framework toward more individualized follow-up decisions.

If the findings are validated, patients with early-stage endometrial cancer could have clearer guidance on how closely their recurrence risk warrants monitoring. The study itself does not change current treatment or testing recommendations.

The takeaway

Molecular profiling is adding detail beyond traditional clinical and pathologic criteria for endometrial cancer. Patients should discuss recurrence risk and follow-up plans with their oncology team as new tools emerge.